Pfenex
10790 Roselle St
San Diego
California
92121
United States
Tel: 858-352-4400
Fax: 858-352-4602
Website: http://www.pfenex.com/
Email: croman@pfenex.com
109 articles about Pfenex
-
PfenexTo Present At The 2015 Barclays Global Healthcare Conference
3/2/2015
-
Pfenex To Present At CALBIO 2015
2/27/2015
-
Pfenex To Present At The 2015 RBC Capital Markets' Healthcare Conference
2/13/2015
-
Pfenex, Hospira Pursue Lucentis Biosimilar in $342 Million Pact
2/11/2015
-
Pfenex Inc. To Present At The 17th Annual Biotechnology Industry Organization (BIO) CEO And Investor Conference
1/29/2015
-
Pfenex Inc. Announces Active IND And Additional BARDA Funding For Recombinant Anthrax Vaccine Program, Px563L
12/22/2014
-
Pfenex Inc. Reports Third Quarter 2014 Results And Provides Business Update
11/14/2014
-
Pfenex Inc. To Report Third Quarter 2014 Results And Provide Business Update On Thursday, November 13, 2014
11/6/2014
-
Pfenex Inc. And PATH Partner On Vaccines
10/10/2014
-
Pfenex Inc. To Present At 13th Annual Biotechnology Industry Organization (BIO) Investor Forum
10/2/2014
-
Pfenex Inc. Added To Both Russell Microcap® Index And Russell Global Indexes
10/2/2014
-
Pfenex Inc. Adds New Board Member
9/25/2014
-
Pfenex Inc. To Present At Upcoming Industry Conference On September 26
9/19/2014
-
Pfenex Inc. Reports Second Quarter 2014 Results And Provides Business Update
9/2/2014
-
San Diego Biotech Pfenex Inc. Prices IPO At $6 Per Share, Below Downwardly Revised $8 Expectation
7/24/2014
-
San Diego Biotech Pfenex Inc. Slashes Proposed Range To $8 A Share, Eyes $65 Million In IPO Debut
7/18/2014
-
San Diego's Pfenex Inc. Files For A $75 Million IPO To Fund Development Of Wet AMD Drug
6/9/2014
-
Pfenex Inc. Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine
12/17/2013
-
Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of Its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of Its Anthrax Vaccine
11/5/2013
-
Pfenex Inc. Awarded a Subcontract by Leidos to Develop a Scalable cGMP Production Process for a Second Key Malaria Antigen
10/29/2013